Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects


Published: June 10, 2009
Abstract Views: 130
PDF: 371
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Liposomes are lamellar structures composed of a lipid bilayer. They are used as carriers for different drugs. The present paper reviews the use of intravenous liposomal anticancer drugs in dermato-oncology. The broadest application is found today for liposomal anthracyclines, i.e. doxorubicin and daunorubicin. There is clear evidence for liposomal drug efficacy and safety cutaneous T-cell lymphoma (CTCL) with response rates about 80-90%. Randomized, double-blinded prospective controlled trials are on the way.

Supporting Agencies


Wollina, U. (2009). Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.493

Downloads

Citations